US company COVAXX has announced $2.8bn advanced purchase commitments of over 140 million doses of its UB-612 vaccine to be delivered in countries including Brazil, Ecuador and Peru.

UB-612 is a multitope synthetic peptide vaccine that can potentially activate both B and T-cell arms of the immune system.

The latest development follows the initiation of human trials in Taiwan.

Also, Covaxx signed a deal with Brazilian clinical diagnostic firm Diagnosticos da America in September to conduct Phase II / III trials and distribute vaccines within Brazil.

The Phase I trials of UB-612 are nearing completion in Taiwan and the company made a deal with the University of Nebraska Medical Center (UNMC) to conduct trials in the US.

The company will also initiate Phase II / III clinical trials by the end of this year or first half of next year in Asia, Latin America and the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

COVAXX co-founder and CEO Mei Mei Hu said: “In parallel with the expedited clinical development of UB-612, we are working to help countries with the greatest unmet needs customise their plans for vaccine studies, supply and distribution.”

Last month, the company entered into a global logistics partnership with shipping and integrated logistics provider Maersk for enabling transportation and supply chain services for delivering UB-612 globally.

COVAXX co-founder and vice-chairman Dr Peter Diamandis said: “Our vaccine has the following key attributes that make it potentially best in class: First, it is boostable. Covid-19 is not ‘one and done’ and populations will likely require boosters to protect against the virus.

“Second, the vaccine is stable at 2-8C and can be delivered via existing distribution infrastructure and normal refrigeration; Third, from preliminary data, UB-612 has observed minimal reactogenicity (i.e. no fevers, chills or systemic issues).”

In addition, COVAXX’s manufacturing facilities are well-positioned to produce 100 million doses in the first half of next year and up to one billion by next year-end.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now